BioLineRx (BLRX) Operating Expenses (2013 - 2025)

BioLineRx's Operating Expenses history runs 13 years deep, the most recent figure standing at -$3.5 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 6.37% year-over-year to -$3.5 million; the TTM figure through Dec 2025 stood at -$11.2 million (up 27.36% YoY), while the FY2025 annual figure was -$11.2 million, up 27.36% from the prior year.
• Operating Expenses was -$3.5 million for Q4 2025 at BioLineRx, down from -$2.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $4.3 million in Q2 2022 to a low of -$6.3 million in Q4 2021.
• Historically, Operating Expenses has averaged -$3.5 million across 5 years, with a median of -$4.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses tumbled 199.19% in 2023, then jumped 35.52% in 2025.
• A 5-year view of Operating Expenses shows it stood at -$6.3 million in 2021, then climbed by 20.2% to -$5.0 million in 2022, then slipped by 5.19% to -$5.3 million in 2023, then increased by 28.79% to -$3.8 million in 2024, then climbed by 6.37% to -$3.5 million in 2025.
• The last three Operating Expenses figures came in at -$3.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.